Granulosa Cell Tumor Molecular Mechanisms: The lab has pioneered the development of numerous granulosa cell tumor models including isogenic cell culture lines, xenograft animal models, and high-fidelity genetically-engineering animal models. Using these models, members of the lab apply cutting-edge multi-omic approaches to understanding the molecular and gene regulatory changes that underpin the development and recurrence of this rare disease.
Granulosa Cell Tumor Therapeutics: Members of the lab have used high-throughput drug screening platforms and functional genomics to discover novel therapeutic vulnerabilities. These discoveries are in turn being used to develop and launch new early-phase clinical trials in the treatment of ovarian granulosa cell tumors.
Granulosa Cell Tumor Clinical Data Registry: The lab maintains an IRB-approved clinical data registry to track and analyze clinical outcomes for all women seen at MD Anderson Cancer Center with a diagnosis of ovarian granulosa cell tumor (or other form of ovarian sex cord/stromal tumor). These data have led to key insights into the efficacy of therapeutic strategies.
Liquid Biopsy Detection of Structural Variants in High Grade Serous Ovarian Cancer: The lab is developing a novel detection platform for the tumor- and subclone-informed detection of circulating tumor DNA from women undergoing upfront treatment for high-grade serous ovarian cancer.